title: Assessment of bone status in inhaled corticosteroid user asthmatic patients with an ultrasound measurement method.
abstract: BACKGROUND
  The effect of inhaled corticosteroid (ICS) on the bone status of asthmatic patients is still uncertain, because it can differ by race and because there have been few cases in Japan. In this study, the bone status of ICS users with asthma was evaluated in an actual clinical setting in Japan.
  
  
  METHODS
  In 7 participating hospitals, ICS users with asthma and control subjects were age- and gender-matched and recruited into this study. To assess bone status, ultrasound measurements of each individual's calcaneus were made using an AOS-100. The ratio of the osteo sono-assessment index (OSI) to the average OSI corrected for age and gender was denoted as %OSI and used for quantitative assessment. The second %OSI measurement was performed 6 months after the first %OSI one. During the study period, individual treatment remained unchanged.
  
  
  RESULTS
  There were no significant differences in the 1st and 2nd %OSI between the ICS users and control subjects. However, the 2nd %OSI significantly decreased compared with 1st %OSI in female ICS users, although there were no significant changes in the male and female control subjects and male ICS users.
  
  
  CONCLUSIONS
  The 6 month management of asthma in the actual clinical setting, including regular ICS use, might have a harmful influence on the bone status of female asthmatic patients. It may be necessary to manage and treat female patients for potent corticosteroid-induced osteoporosis, although further analyses of bone status in asthma patient ICS users will be required.
authors.affiliation: Department of Respiratory Medicine, Nanbugo General Hospital, Niigata, Japan.
authors.forename: Mayumi
authors.initials: M
authors.lastname: Sasagawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Jun-ichiro J
authors.initials: JJ
authors.lastname: Kazama
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Koya
authors.forename: Takuro
authors.initials: T
authors.lastname: Sakagami
authors.forename: Kazuo
authors.initials: K
authors.lastname: Suzuki
authors.forename: Katsuhito
authors.initials: K
authors.lastname: Hara
authors.forename: Hideo
authors.initials: H
authors.lastname: Satoh
authors.forename: Katsuya
authors.initials: K
authors.lastname: Fujimori
authors.forename: Fumitoshi
authors.initials: F
authors.lastname: Yoshimine
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Satoh
authors.forename: Ichiei
authors.initials: I
authors.lastname: Narita
authors.forename: Masaaki
authors.initials: M
authors.lastname: Arakawa
authors.forename: Fumitake
authors.initials: F
authors.lastname: Gejyo
authors.forename: Eiichi
authors.initials: E
authors.lastname: Suzuki
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects*; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D001842:Bone and Bones / Q000000981:diagnostic imaging* / Q000187:drug effects*; D002111:Calcaneus / Q000000981:diagnostic imaging / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014463:Ultrasonography
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents